<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02420899</url>
  </required_header>
  <id_info>
    <org_study_id>40068860-9</org_study_id>
    <nct_id>NCT02420899</nct_id>
  </id_info>
  <brief_title>Different Doses of Rosuvastatin Therapy on Regression of Critical Coronary Atherosclerosis in ACS Patients</brief_title>
  <official_title>Effect of Different Doses of Rosuvastatin Therapy on Regression of Critical Coronary Atherosclerosis in Chinese ACS Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Friendship Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Friendship Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether Rosuvastatin 10mg/d or 20mg/d for 36 weeks
      can regress critical coronary atherosclerosis as determined by IVUS imaging in Chinese Acute
      Coronary Syndrome (ACS) patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, open-label, parallel group study to evaluate the efficacy of
      rosuvastatin 10mg/d or 20mg/d on critical coronary atherosclerosis in Chinese ACS patients.
      The anticipated duration of the study is approximately 36 weeks, Patients with angiographic
      luminal diameter narrowing in any non-culprit site between 40%-70% will be enrolled from the
      study site. The primary efficacy parameter is the percent change of Total Atheroma Volume
      (TAV) of critical coronary atherosclerosis after 36 weeks of treatment.

      For inclusion in the study subjects should fulfill the following criteria:

        1. Provision of informed consent prior to any study specific procedures

        2. 18 to 75 years old ACS patients, male or female

        3. The angiographic luminal diameter narrowing in any non-culprit site is between 40%-70%

        4. statin-naive, defined as receiving no statin therapy within 3 monthsThe primary efficacy
           variable of the study is percent change of TAV from baseline after rosuvastatin 10mg/d
           or 20mg/d for 36 weeks as determined by IVUS imaging.

      The secondary efficacy variables are:

        -  Change of blood lipid level from baseline at 12th, 24th, 36nd week

        -  Change of inflammatory markers from baseline at 36nd week

        -  Change of Percent Atheroma Volume (PAV) as determined by IVUS imaging at 36nd week
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>April 2015</start_date>
  <completion_date type="Anticipated">July 2016</completion_date>
  <primary_completion_date type="Anticipated">July 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent Atheroma Volume (PAV)</measure>
    <time_frame>36 weeks</time_frame>
    <description>Percent Atheroma Volume</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>inflammatory marker levels</measure>
    <time_frame>36 weeks</time_frame>
    <description>MCP-1, VCAM-1 level and mRNA level of ICAM-1, CCR2</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Total Atheroma Volume (TAV)</measure>
    <time_frame>36 weeks</time_frame>
    <description>Total Atheroma Volume</description>
  </other_outcome>
  <other_outcome>
    <measure>lipid level</measure>
    <time_frame>36 weeks</time_frame>
    <description>LDL-C,HDL-C,TC,TG</description>
  </other_outcome>
  <other_outcome>
    <measure>safety and tolerability as assessed by blood biochemistry, blood routines and urine routines</measure>
    <time_frame>36 weeks</time_frame>
    <description>blood biochemistry, blood routines and urine routines</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Acute Coronary Syndrome</condition>
  <arm_group>
    <arm_group_label>Statins,lipid-lowering drugs</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>rosuvastatin 10mg or 20mg per day，pro</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rosuvastatin</intervention_name>
    <description>10mg/d or 20mg/d,po</description>
    <arm_group_label>Statins,lipid-lowering drugs</arm_group_label>
    <other_name>crestor</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        1.Provision of informed consent prior to any study specific procedures; 2.18 to 75 years
        old ACS patients, male or female; 3.The angiographic luminal diameter narrowing in any
        non-culprit site is between 40%-70%; 4.statin-naive, defined as receiving no statin therapy
        within 3 months;

        Exclusion Criteria:

          1. Have received statin therapy within 3 months;

          2. The angiographic luminal diameter narrowing in any coronary vessels is more than 70%;

          3. Active liver disease, ALT≥3*ULN;

          4. Renal function damage, CrCl＜30ml/min;

          5. Myopathy;

          6. Pregnancy, lactation female;

          7. Using cyclosporine;

          8. Patients with uncontrolled triglyceride levels TG≥5.65 mmol／L;

          9. Poorly controlled diabetes (HbA1c≥10%）Hypersensitivity to rosuvastatin or any of the
             recipients.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hui Chen, doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing Friendship Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Qingbo Liu, master</last_name>
    <phone>13552328830</phone>
    <email>1035105896@qq.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Liu Qingbo</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100050</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Qingbo Liu, master</last_name>
      <phone>13552328830</phone>
      <email>1035105896@qq.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>1.Liao J K, Laufs U. Pleiotropic effects of statins[J]. Annual review of pharmacology and toxicology, 2005, 45: 89. 2.Davignon J. Beneficial cardiovascular pleiotropic effects of statins[J]. Circulation, 2004, 109(23 suppl 1): III-39-III-43. 3.Falk E, Shah P K, Fuster V. Coronary plaque disruption[J]. Circulation, 1995, 92(3): 657-671. 4. Nissen SE, Nicholls SJ, Sipahi I, et al.Effect of very high-intensity statin therapy on regression of coronary atherosclerosis:the ASTEROID trial. JAMA, 2006; 295: 1556-65. 5. Lee CW, et al. Comparison of Effects of Atorvastatin(20mg) Versus Rosuvastatin(10mg) Therapy on Mild Coronary Atherosclerosis Plaques(from the ARTMAP Trial).Am J Cardiol, 2012; 109:1700-1704.</citation>
  </reference>
  <verification_date>June 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 13, 2015</study_first_submitted>
  <study_first_submitted_qc>April 17, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 20, 2015</study_first_posted>
  <last_update_submitted>June 6, 2015</last_update_submitted>
  <last_update_submitted_qc>June 6, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 9, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beijing Friendship Hospital</investigator_affiliation>
    <investigator_full_name>Hui Chen</investigator_full_name>
    <investigator_title>Hui Chen,Director,Clinical Professor,Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>IVUS</keyword>
  <keyword>ACS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atherosclerosis</mesh_term>
    <mesh_term>Acute Coronary Syndrome</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosuvastatin Calcium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

